EDITClinical Trials•globenewswire•August 28, 2025 at 08:01 PM

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Sentiment:Positive (70)

Summary

(NASDAQ:EDIT) CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 28, 2025 by globenewswire